Albany, NY -- (SBWIRE) -- 09/17/2019 -- Dravet Syndrome Market Insights, Epidemiology and Market Forecast- 2028
1. Dravet Syndrome total incident population in the 9 Major Markets was 36,301 in 2017.
2. The United States accounted for the maximum number of Dravet Syndrome patients with 20,731 cases in 2017 followed by Germany with 2,896 cases
3. The total number of deaths associated with Dravet Syndrome in Australia was 1,085 in 2017.
DelveInsight launched a new report on Dravet Syndrome Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Dravet Syndrome market report covers a descriptive overview and comprehensive insight of the Dravet Syndrome epidemiology and Dravet Syndrome market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Dravet Syndrome market report provides insights on the current and emerging therapies.
3. Dravet Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Dravet Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dravet Syndrome market.
Request for sample pages
"Nearly 73% of the patients die before the age of 10 years."
Dravet syndrome current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the patient's and the family's quality of life. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections.
Despite these shortcomings, in recent years Dravet syndrome has received significant attention from the pharmaceutical industry, and the pipeline has matured to include not only symptomatic but also disease-modifying Dravet syndrome treatment. At present, Pharmacological management of Dravet syndrome focuses largely on the use antiepileptic drugs such as Valproic Acid, Clobazam, Topiramate, Levetiracetam, Zonisamide and Stiripentol.
The above-mentioned therapies currently hold the Dravet Syndrome market in the 9MM. However, the dynamics of Dravet Syndrome market is anticipated to change during the forecast period. Companies have shifted their focus on the development of second-generation therapeutics that follow the step of the most advanced cannabidiol formulation (Epidiolex) and the most advanced serotonergic drug (ZX008). Most of these compounds would have the potential to treat other forms of epilepsy and are expected to hit the Dravet syndrome market during the forecasted period of (2019-2028).
The launch of the emerging therapies is expected to significantly impact Dravet syndrome treatment scenario in the upcoming years:-
Drugs covered
1. FINTEPLA
And many others
The key players in market are:
1. Zogenix
And many others
Table of contents
1. Key Insights
2. Dravet Syndrome Market Overview at a Glance
3. Dravet Syndrome Disease Background and Overview
4. Dravet Syndrome Epidemiology and Patient Population
5. Dravet Syndrome Country Wise-Epidemiology
6. United States
7. EU-5
8. Germany
9. France
10. Italy
11. Spain
12. United Kingdom
13. Austria
14. Japan
15. Australia
16. Dravet Syndrome Treatment
17. Unmet Needs
18. Dravet Syndrome Marketed Drugs
18.1.Diacomit: Biocodex
18.2. Epidiolex: GW Pharmaceuticals
19. Dravet Syndrome Emerging Therapies
19.1. FINTEPLA: Zogenix
20. Dravet Syndrome 9 Major Market Analysis
21. Market Outlook by Country
21.1. The United States: Market Outlook
21.2. United States Market Size
21.3. EU-6 Countries: Market Outlook
21.4. Germany Market Size
21.5. France Market Size
21.6. Italy Market Size
21.7. Spain Market Size
21.8. The United Kingdom Market Size
21.9. Austria Market Size
21.10. Japan: Market Outlook
21.11. Japan: Market Size
22. Market Drivers
23. Market Barriers
24. Appendix
25. Dravet Syndrome Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight